文献速递中毒与环境急症

药房纳洛酮常备医嘱与社区阿片类致死率随时间的变化

Pharmacy Naloxone Standing Order and Community Opioid Fatality Rates Over Time.
PubMed 文献 · JAMA Netw Open · 2024-08-01
一句话结论马萨诸塞州351个市镇中断时间序列分析显示,实施药房纳洛酮常备医嘱配药与阿片类致死率年化率比0.84(95%CI 0.78-0.91)的逐步下降相关。

该回顾性多地点研究采用中断时间序列分析,纳入马萨诸塞州351个市镇2013年1月1日至2018年12月31日共24个季度的数据,评估药房纳洛酮常备医嘱配药与市镇阿片类致死率的关系。214个市镇(60.9%)在研究期间报告了常备医嘱纳洛酮配药。2013年第一季度基线时,最终实施常备医嘱的市镇阿片类致死率高于从未实施者(每10万人3.51 vs 1.03例死亡;P < .001)。调整市镇层面社会人口学和阿片类预防因素后,实施常备医嘱纳洛酮配药后阿片类致死率斜率显著下降(年化率比0.84;95%CI 0.78-0.91;P < .001),调整模型中未见显著水平变化。作者认为这些发现支持扩大纳洛酮可及性,包括非处方纳洛酮,作为应对阿片类过量的多层面措施的一部分。

要点

  • 马萨诸塞州351个市镇中,214个(60.9%)在研究期间报告药房常备医嘱纳洛酮配药。
  • 2013年第一季度基线时,最终实施常备医嘱的市镇阿片类致死率高于从未实施者(每10万人3.51 vs 1.03例死亡;P < .001)。
  • 调整市镇层面社会人口学和阿片类预防因素后,实施常备医嘱纳洛酮配药后阿片类致死率斜率显著下降(年化率比0.84;95%CI 0.78-0.91;P < .001)。
  • 调整模型中未见阿片类致死率的显著水平变化。
  • 敏感性分析得到相似且显著的发现。

适用人群与场景

  • 马萨诸塞州351个市镇,研究期间为2013年1月1日至2018年12月31日共24个季度。
  • 351个市镇的中位(IQR)人口规模为10 314(3635至21 781)人,女性比例均值(SD)为51.1%(2.8个百分点)。
  • 常备医嘱纳洛酮配药数据来自2个来源,覆盖马萨诸塞州所有主要连锁药房和许多独立药房,占零售药房的70%。

研究设计与关键结果

  • 研究类型为回顾性多地点中断时间序列分析,纳入马萨诸塞州351个市镇24个季度(2013年1月1日至2018年12月31日)的数据,数据分析时间为2021年12月至2023年11月。
  • 主要暴露为以首次常备医嘱纳洛酮配药的季度作为实际实施起点;主要结局为来自马萨诸塞州生命记录与统计登记处的市镇每10万人阿片类致死率。
  • 214个市镇(60.9%)在研究期间报告了常备医嘱纳洛酮配药。
  • 2013年第一季度基线时,最终实施常备医嘱的市镇阿片类致死率高于从未实施者(每10万人3.51 vs 1.03例死亡;P < .001)。
  • 调整市镇层面社会人口学和阿片类预防因素后,实施常备医嘱纳洛酮配药后阿片类致死率斜率显著下降(年化率比0.84;95%CI 0.78-0.91;P < .001), compared with the municipalities that did not implement standing-order naloxone。
  • 调整模型中未见阿片类致死率的显著水平变化;敏感性分析得到相似且显著的发现。

证据类型、等级与局限

  • 证据类型:回顾性多地点中断时间序列分析。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,与未实施常备医嘱纳洛酮项目的社区相比,社区药房通过常备医嘱配发纳洛酮与阿片类致死率相对、逐步且显著的下降相关。
  • 作者认为,这些发现支持扩大纳洛酮可及性,包括非处方纳洛酮,作为应对阿片类过量的多层面措施的一部分。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

IMPORTANCE: Despite the proliferation of pharmacy standing-order naloxone dispensing across many US states before the change to over-the-counter status, few policy analyses have evaluated the implementation of pharmacy naloxone standing orders in addressing opioid overdose fatality among communities.

OBJECTIVE: To determine whether the implementation of pharmacy standing-order naloxone was associated with lower opioid fatality rates compared with communities without pharmacies with standing-order naloxone.

DESIGN, SETTING, AND PARTICIPANTS: This retrospective multisite study was conducted with an interrupted time series analysis across 351 municipalities in Massachusetts over 24 quarters (from January 1, 2013, through December 31, 2018). Standing-order naloxone dispensing data were collected from 2 sources for all major chain pharmacies and many independent pharmacies, covering 70% of retail pharmacies in Massachusetts. Municipalities had various standing-order naloxone implementation inceptions during the study period. Data were analyzed from December 2021 to November 2023.

EXPOSURE: The main exposure was measured by the first quarter with standing-order naloxone dispensation as the actual implementation inception.

MAIN OUTCOMES AND MEASURES: The primary study outcome was municipal opioid fatality rate per 100 000 population obtained from the Massachusetts Registry of Vital Records and Statistics.

RESULTS: The median (IQR) population size across 351 municipalities was 10 314 (3635 to 21 781) people, with mean (SD) proportion of female individuals was 51.1% (2.8 percentage points). Pharmacies from 214 municipalities (60.9%) reported dispensing standing-order naloxone over the study period. At the baseline of the first quarter of 2013, municipalities that eventually had standing-order naloxone had greater quarterly opioid fatality rates compared with those that never implemented standing-order naloxone (3.51 vs 1.03 deaths per 100 000 population; P < .001). After adjusting for municipal-level sociodemographic and opioid prevention factors, there was significant slope decrease of opioid fatality rates (annualized rate ratio, 0.84; 95% CI, 0.78-0.91; P < .001) following standing-order naloxone dispensing, compared with the municipalities that did not implement standing-order naloxone. There were no significant level changes of opioid fatality rates in the adjusted models. Sensitivity analyses yielded similar and significant findings.

CONCLUSIONS AND RELEVANCE: These findings suggest that community pharmacy dispensing of naloxone with standing orders was associated with a relative, gradual, and significant decrease in opioid fatality rates compared with communities that did not implement the standing-order naloxone program. These findings support the expansion of naloxone access, including over-the-counter naloxone as part of a multifaceted approach to address opioid overdose.

来源:JAMA Netw Open,查看原文。版权归原作者所有。

参考来源

  1. Xuan Z, Walley AY, Yan S, et al. Pharmacy Naloxone Standing Order and Community Opioid Fatality Rates Over Time. JAMA Netw Open. 2024. PMID: 39207758. doi:10.1001/jamanetworkopen.2024.27236

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。